Dividend investing is a tried-and-true strategy for generating strong, steady returns in economies both good and bad. But as corporate America's slew of dividend cuts and suspensions over the past few years has demonstrated, it's not enough simply to buy a high yield. You also need to make sure those payouts are sustainable.

Let's examine how Bristol-Myers Squibb (NYSE: BMY) stacks up in four critical areas to determine whether it's a dividend dynamo or a disaster in the making.

1. Yield
First and foremost, dividend investors like a large forward yield. But if a yield gets too high, it may reflect investors' doubts about the payout's sustainability. If investors had confidence in the stock, they'd be buying it, driving up the share price and shrinking the yield.

Bristol-Myers Squibb yields 4.8% -- moderate and worthy of further investigation.

2. Payout ratio
The payout ratio might be the most important metric for judging dividend sustainability. It compares the amount of money a company paid out in dividends last year to the earnings it generated. A ratio that's too high -- say, greater than 80% of earnings -- indicates that the company may be stretching to make payouts it can't afford, even when its dividend yield doesn't seem particularly high.

Bristol-Myers Squibb's payout ratio is a moderate 66%.

3. Balance sheet
The best dividend payers have the financial fortitude to fund growth and respond to whatever the economy and competitors throw at them. The interest coverage ratio indicates whether a company is having trouble meeting its interest payments -- any ratio less than five is a warning sign. Meanwhile, the debt-to-equity ratio is a good measure of a company's total debt burden.

Bristol-Myers Squibb's debt-to-equity ratio is 34%. Its interest coverage rate is 45 times.

4. Growth
A large dividend is nice; a large growing dividend is even better. To support a growing dividend, we also want to see earnings growth.

Let's examine how Bristol-Myers Squibb stacks up next to its peers:


5-Year Annual Earnings-per-share growth

5-Year Annual Dividend Growth

Bristol-Myers Squibb



Pfizer (NYSE: PFE)



Abbott Labs (NYSE: ABT)



Eli Lilly (NYSE: LLY)



Source: Capital IQ, a division of Standard & Poor's.

The Foolish bottom line
Bristol-Myers Squibb exhibits a fairly clean dividend bill of health. It has a moderate payout ratio and reasonable leverage. Dividend investors will want to watch the company to ensure that it's able to increase those earnings too. Yesterday's unexpected Eliquis announcement shouldn't hurt that effort.

To stay up-to-speed on the top news and analysis on Bristol-Myers Squibb, or any other stock, simply click here to add it to your stock watchlist. If you don't have one yet, you can create a watchlist of your favorite stocks by clicking here.

Ilan Moscovitz doesn't own shares of any companies mentioned. You can follow him on Twitter @TMFDada. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Abbott Laboratories and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.